Cargando…
Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients
AIMS: Cardiac allograft vasculopathy (CAV) is the major cause of increased morbidity and mortality after heart transplantation. Peripheral endothelial dysfunction (PED) is associated with early atherosclerosis and future risk of major adverse cardiovascular events (MACE) in non‐heart transplant popu...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712915/ https://www.ncbi.nlm.nih.gov/pubmed/34510802 http://dx.doi.org/10.1002/ehf2.13610 |
_version_ | 1784623663367061504 |
---|---|
author | Ozcan, Ilke Toya, Takumi Corban, Michel T. Ahmad, Ali Lerman, Lilach O. Kushwaha, Sudhir S. Lerman, Amir |
author_facet | Ozcan, Ilke Toya, Takumi Corban, Michel T. Ahmad, Ali Lerman, Lilach O. Kushwaha, Sudhir S. Lerman, Amir |
author_sort | Ozcan, Ilke |
collection | PubMed |
description | AIMS: Cardiac allograft vasculopathy (CAV) is the major cause of increased morbidity and mortality after heart transplantation. Peripheral endothelial dysfunction (PED) is associated with early atherosclerosis and future risk of major adverse cardiovascular events (MACE) in non‐heart transplant population. We aimed to investigate the association of PED with future MACE, and plaque progression assessed by intravascular ultrasound (IVUS) after heart transplantation. METHODS AND RESULTS: We included 66 transplant patients who underwent serial IVUS surveillance for CAV and baseline assessment of peripheral endothelial function using reactive hyperaemia peripheral arterial tonometry. PED was defined as reactive hyperaemia index < 2. The primary endpoint of the study was to investigate the association of PED with CAV progression assessed by intravascular ultrasound (IVUS). CAV progression was assessed as the change (Δ) in plaque volume divided by segment length, and Δ plaque index (plaque volume/vessel volume), adjusted for the time between IVUS measurements (median 3.0 [2.2, 3.1] years). The secondary endpoint was to investigate the association between PED and future MACE, which was defined as any incident of revascularization, heart failure hospitalization, stroke, myocardial infarction, re‐transplantation, and death. Patients with PED (n = 27) had more yearly plaque progression (0.50 ± 0.66 vs. 0.15 ± 0.50 mm(3)/mm/year, P = 0.02) and a higher Δ plaque index (2.41 ± 2.53% vs. 0.69 ± 2.22%, P = 0.01). Patients with PED were more likely to experience MACE during a median follow‐up of 8.2 years (interquartile range [7.6, 8.4]), after adjustment for potential cofounders such as age, high‐density lipoprotein cholesterol levels, total rejection score, baseline International Society for Heart & Lung Transplantation CAV grade, and indication of transplantation. (hazard ratio 2.15, 95% confidence interval [1.09, 4.23], P = 0.03). CONCLUSIONS: Peripheral endothelial dysfunction is associated with increased plaque progression and adverse long‐term cardiovascular outcomes in transplant patients. PED assessment might be a useful clinical tool for risk stratification after heart transplantation. |
format | Online Article Text |
id | pubmed-8712915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87129152022-01-04 Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients Ozcan, Ilke Toya, Takumi Corban, Michel T. Ahmad, Ali Lerman, Lilach O. Kushwaha, Sudhir S. Lerman, Amir ESC Heart Fail Original Articles AIMS: Cardiac allograft vasculopathy (CAV) is the major cause of increased morbidity and mortality after heart transplantation. Peripheral endothelial dysfunction (PED) is associated with early atherosclerosis and future risk of major adverse cardiovascular events (MACE) in non‐heart transplant population. We aimed to investigate the association of PED with future MACE, and plaque progression assessed by intravascular ultrasound (IVUS) after heart transplantation. METHODS AND RESULTS: We included 66 transplant patients who underwent serial IVUS surveillance for CAV and baseline assessment of peripheral endothelial function using reactive hyperaemia peripheral arterial tonometry. PED was defined as reactive hyperaemia index < 2. The primary endpoint of the study was to investigate the association of PED with CAV progression assessed by intravascular ultrasound (IVUS). CAV progression was assessed as the change (Δ) in plaque volume divided by segment length, and Δ plaque index (plaque volume/vessel volume), adjusted for the time between IVUS measurements (median 3.0 [2.2, 3.1] years). The secondary endpoint was to investigate the association between PED and future MACE, which was defined as any incident of revascularization, heart failure hospitalization, stroke, myocardial infarction, re‐transplantation, and death. Patients with PED (n = 27) had more yearly plaque progression (0.50 ± 0.66 vs. 0.15 ± 0.50 mm(3)/mm/year, P = 0.02) and a higher Δ plaque index (2.41 ± 2.53% vs. 0.69 ± 2.22%, P = 0.01). Patients with PED were more likely to experience MACE during a median follow‐up of 8.2 years (interquartile range [7.6, 8.4]), after adjustment for potential cofounders such as age, high‐density lipoprotein cholesterol levels, total rejection score, baseline International Society for Heart & Lung Transplantation CAV grade, and indication of transplantation. (hazard ratio 2.15, 95% confidence interval [1.09, 4.23], P = 0.03). CONCLUSIONS: Peripheral endothelial dysfunction is associated with increased plaque progression and adverse long‐term cardiovascular outcomes in transplant patients. PED assessment might be a useful clinical tool for risk stratification after heart transplantation. John Wiley and Sons Inc. 2021-09-12 /pmc/articles/PMC8712915/ /pubmed/34510802 http://dx.doi.org/10.1002/ehf2.13610 Text en © 2021 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Ozcan, Ilke Toya, Takumi Corban, Michel T. Ahmad, Ali Lerman, Lilach O. Kushwaha, Sudhir S. Lerman, Amir Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients |
title | Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients |
title_full | Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients |
title_fullStr | Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients |
title_full_unstemmed | Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients |
title_short | Peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients |
title_sort | peripheral microvascular dysfunction is associated with plaque progression and adverse long‐term outcomes in heart transplant patients |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712915/ https://www.ncbi.nlm.nih.gov/pubmed/34510802 http://dx.doi.org/10.1002/ehf2.13610 |
work_keys_str_mv | AT ozcanilke peripheralmicrovasculardysfunctionisassociatedwithplaqueprogressionandadverselongtermoutcomesinhearttransplantpatients AT toyatakumi peripheralmicrovasculardysfunctionisassociatedwithplaqueprogressionandadverselongtermoutcomesinhearttransplantpatients AT corbanmichelt peripheralmicrovasculardysfunctionisassociatedwithplaqueprogressionandadverselongtermoutcomesinhearttransplantpatients AT ahmadali peripheralmicrovasculardysfunctionisassociatedwithplaqueprogressionandadverselongtermoutcomesinhearttransplantpatients AT lermanlilacho peripheralmicrovasculardysfunctionisassociatedwithplaqueprogressionandadverselongtermoutcomesinhearttransplantpatients AT kushwahasudhirs peripheralmicrovasculardysfunctionisassociatedwithplaqueprogressionandadverselongtermoutcomesinhearttransplantpatients AT lermanamir peripheralmicrovasculardysfunctionisassociatedwithplaqueprogressionandadverselongtermoutcomesinhearttransplantpatients |